CORNING, N.Y., October 31, 2006 – BioLife Solutions Inc. (OTC Bulletin Board: BLFS), a leading manufacturer of proprietary cryopreservation solutions for cells and tissue preservation, and Corning Incorporated (NYSE: GLW) today announced the publication of a report that describes the benefits of the combination of the BioLife CryoStor™ CS5 with Corning’s CellBIND® Surface. The integration of these complementary technologies resulted in a significant increase in the survival and attachment of LNCaP cells as compared to traditional solutions and tissue culture treated (TCT) surfaces. The CryoStor/Corning CellBIND Surface combined approach offers a distinct advantage to the pharmaceutical, drug discovery, and toxicity testing industries by enabling researchers to reduce time and effort presently required to collect, store, retrieve and utilize high-quality cryopreserved cells. This thereby increases productivity and cost-effectiveness of in vitro screening processes.
